Skip to main content
. Author manuscript; available in PMC: 2010 Aug 25.
Published in final edited form as: Thromb Haemost. 2009 Oct 26;103(1):224–233. doi: 10.1160/TH09-06-0400

Figure 1. Inhibition of TF-FVIIa activity by anti-TF monoclonal antibodies.

Figure 1

(A) Lipidated recombinant human TF (5 nM) was preincubated with anti-TF antibody (50 nM) for 30 minutes at 37°C, followed by addition of FVIIa (5 nM) (black bars). Alternatively, lipidated recombinant human TF (5 nM) was preincubated with human FVIIa (5 nM) for 30 minutes at 37°C, followed by addition of individual mAb (50 nM) (white bars). The chromogenic substrate S-2288 was added and TF-FVIIa activity measured as described in Materials and Methods. The average percent inhibition of TF-FVIIa activity (± tandard deviation (SD), n = 3) relative to a control reaction without antibody is plotted. (B) Pre-formed TF-FVIIa complex (containing 0.08 nM TF and 0.08 nM FVIIa) was incubated with 0.8 nM of each individual mAb for 30 minutes at 37°C. Factor X was then added to start the activation. Newly formed FXa was then measured using the chromogenic substrate S-2222 as described in Materials and Methods. The average percent inhibition of TF-FVIIa-dependent FX activity (± D, n = 3) relative to a control reaction without antibody is plotted.